Midtown Partners

Skye Bioscience is a San Diego-based pharmaceutical company focused on developing innovative therapeutic solutions for prevalent diseases that lack effective treatments. The company specializes in creating proprietary molecules aimed at addressing inflammatory, fibrotic, and metabolic disorders. It is particularly engaged in the modulation of cannabinoid receptor 1 (CB1) to provide novel treatment options for conditions such as obesity and glaucoma. Among its clinical candidates, Skye Bioscience is advancing nimacimab, an antibody designed to inhibit peripheral CB1 receptors for obesity treatment, and SBI-100 Ophthalmic Emulsion, a CB1 agonist intended for glaucoma management. The company's commitment to research and development positions it to contribute significantly to the biopharmaceutical landscape, particularly in the realm of cannabinoid-based therapeutics.

NetTalk.com, Inc. is a telecommunications provider based in Miami Gardens, Florida, offering digital phone services for residential and commercial customers across North America. Utilizing voice over Internet protocol (VoIP) and session initiation protocol (SIP) technologies, the company specializes in products such as DUO, DUO II, and DUO WIFI, which are analog telephone adapters designed to connect traditional telephones and faxes to local area networks. These devices allow users to access advanced calling features like call forwarding, caller ID, and three-way calling. In addition to its hardware offerings, NetTalk provides the CONNECT mobile application, enabling seamless communication across devices. The company markets its services through direct sales and retail channels, emphasizing affordability and ease of use with a single annual billing cycle. Originally established as Discover Screens, Inc. in 2006, the company rebranded to NetTalk.com, Inc. in 2008.